Aclaris Therapeutics Announces Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Aclaris Therapeutics Announces Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Aclaris Therapeutics Announces Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
aclaris therapeutics宣布向omers life sciences出售OLUMIANt专利权和里程碑，最高可达3150万美元。
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities -
- $26.5 Million Upfront Plus Up to $5.0 Million Milestone -
宾夕法尼亚州韦恩市，2024年7月16日（全球新闻社） - Aclaris Therapeutics, Inc.（NASDAQ：ACRS）是一家专注于开发免疫炎症疾病新型药物候选品的临床阶段生物制药公司，今天宣布将Eli Lilly和Company（Lilly）的OLUMIANT®（baricitinib）销售的净销售额用于治疗斑秃'toa部分Aclaris的未来版税支付和某些里程碑销售给了OMERS之一，是加拿大最大的规定年金计划之一。
根据协议条款，Aclaris已收到2650万美元的预付款，有资格在2024年根据OLUMIANt的某些销售里程碑的实现情况获得多达500万美元的额外支付。作为交换，OMERS已获得Lilly应支付给Aclaris用于从2024年4月1日到根据该许可协议的版税期限结束为止全球净销售额的一部分，以及Lilly在许可协议项下支付给Aclaris的其余周年里程碑支付的100％。
WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the sale of a portion of Aclaris' future royalty payments and certain milestones from Eli Lilly and Company (Lilly) on net sales of OLUMIANT (baricitinib) for the treatment of alopecia areata to OMERS, one of Canada's largest defined benefit pension plans.
2024年7月16日，宣布与Eli Lilly and Company（Lilly）就Olumiant(Baricitinib)治疗斑秃的全球累计净销售额的未来凯瑟琳中Lilly的部分未来的版税支付和某些里程碑的出售向加拿大最大的养老基金之一 OMERS出售了Aclaris Therapeutics, Inc. (NASDAQ: ACRS)，这是一家专注于开发针对免疫炎性疾病的新型药物候选品的临床阶段生物制药公司。
Under the terms of the agreement, Aclaris has received an upfront payment of $26.5 million, and is eligible to receive up to an additional $5.0 million based on the achievement of certain sales milestones for OLUMIANT in 2024. In exchange, OMERS has acquired a portion of the royalty paid by Lilly to Aclaris for worldwide net sales of OLUMIANT for alopecia areata from April 1, 2024 through the remainder of the royalty term under Aclaris' license agreement with Lilly, and 100% of the remaining anniversary milestone payments payable by Lilly to Aclaris under the license agreement.
根据协议的条款，Aclaris Therapeutics已收到2650万美元的预付款，并有资格根据2024年OLUMIANt销售中的某些销售里程碑的实现获得多达500万美元的额外费用。作为交换，OMERS已经获得了Lilly支付给Aclaris的版税的一部分，用于斑秃OLUMIANt的全球净销售额，从2024年4月1日到Aclaris的许可协议到期的剩余版税期限，以及Lilly根据许可协议向Aclaris支付的其余周年里程碑款项的100%。
"This transaction bolsters our balance sheet and provides us with enhanced financial flexibility to pursue a range of value-creating opportunities while continuing to invest in our internal programs," said Dr. Neal Walker, Interim President & CEO and Chair of the Board of Directors of Aclaris. "As we progress with our strategic review, we will continue to pursue available opportunities to enable us to invest in programs that complement and enhance our existing drug development pipeline."
“这笔交易增强了我们的资产负债表，并为我们提供了增强的财务灵活性，以追求一系列创造价值的机会，同时继续投资于我们的内部项目，”Aclaris董事会主席、临时总裁兼CEO Neal Walker博士表示。“随着我们战略审核的进展，我们将继续寻求可用机会，使我们能够投资于与我们现有药物开发管线相补充和增强的项目。”
OLUMIANT is a registered trademark of Eli Lilly and Company.
OLUMIANt是Eli Lilly and Company的注册商标。
Aclaris Therapeutics Contact:
Aclaris Therapeutics 联系方式：
investors@aclaristx.com
investors@aclaristx.com
Source: Aclaris Therapeutics, Inc.
来源：aclairs therapeutics, Inc.